imatinib mesylate has been researched along with Coronary Restenosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirono, S; Makiyama, Y; Ozawa, T; Toba, K | 1 |
| Dirschinger, J; Goos, C; Hausleiter, J; Heemann, U; Kastrati, A; Mehilli, J; Pache, J; Pogatsa-Murray, G; Schömig, A; Schühlen, H; Zohlnhöfer, D | 1 |
1 trial(s) available for imatinib mesylate and Coronary Restenosis
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Benzamides; Coronary Angiography; Coronary Disease; Coronary Restenosis; Creatinine; Double-Blind Method; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Secondary Prevention; Stents | 2005 |
1 other study(ies) available for imatinib mesylate and Coronary Restenosis
| Article | Year |
|---|---|
[Application of selective tyrosine kinase inhibitor to the prevention of coronary restenosis after PCI].
Topics: Angioplasty, Balloon, Coronary; Benzamides; Coronary Restenosis; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |